Abstract
Pulmonary hypertension secondary to lung diseases, as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), is a relatively common condition with a bad prognosis. During the last World Congress in Nizza, detailed instructions about pulmonary hypertension secondary to lung diseases were provided. Long-term oxygen therapy is not able to normalize pulmonary artery pressure (PAP) values or to counteract vascular remodeling; the use of specific drug for pulmonary hypertension secondary to COPD or IPF, especially in severe forms, has often been suggested, but full indications have not yet been supplied.
Translated title of the contribution | Pulmonary hypertension secondary to parenchimal lung diseases: Treatment perspectives |
---|---|
Original language | Italian |
Pages (from-to) | 131-136 |
Number of pages | 6 |
Journal | Rassegna di Patologia dell'Apparato Respiratorio |
Volume | 31 |
Issue number | 3 |
Publication status | Published - 2016 |
ASJC Scopus subject areas
- Pathology and Forensic Medicine
- Pulmonary and Respiratory Medicine